Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q2 2021 Oncopeptides AB Earnings Call Transcript

Aug 19, 2021 / 10:00AM GMT
Release Date Price: kr32.54 (+14.07%)
Operator

Welcome to the Oncopeptides Audiocast with teleconference Q2 2021. (Operator Instructions)

Today, I am pleased to present Marty Duvall, CEO. Please go ahead with your meeting.

Martin J. Duvall;publ;CEO
Oncopeptides AB

()-

Good morning, and thanks for listening to the Oncopeptides Q2 webcast. It's been a pivotal quarter for us, and we're at an important inflection point for the company. In 2021, we've experienced some dramatic swings in our market price from a high of SEK 215 to the lows of the past week. But through it all, there's been one constant and that constant is confidence, our one Oncopeptides team confidence, confidence in our platform, confidence in our lead drug, confidence in our data, confidence in the hope that we bring to patients and confidence in one another. Following an encouraging launch of Pepaxto in the United States, the challenge in the second half of 2021 will be reaching common ground with regulatory bodies, the FDA, in particular, on the strength of our pivotal Phase III OCEAN trial.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot